UMiami ibogaine IND coverage will outpace actual enrolling-trial milestones by a wide margin through November 2026.

There will be a huge wave of news coverage about the University of Miami's ibogaine application, but the actual clinical trial — where real patients get treated and data gets collected — won't meaningfully begin before November 2026. The application itself (called an IND, or Investigational New Drug application) is just paperwork giving researchers permission to try. Political involvement, including interest from Trump-aligned figures, will fuel coverage that makes things sound further along than they are.

INDs are paperwork; enrollment is months out. Political theater and Trump's involvement guarantee coverage volume dwarfs clinical substance.